The kidney, the heart and the receptor nobody was looking for

If you want to predict what a GLP-1 receptor agonist will do to a person, the most informative document is not a dose-response curve. It is a receptor expression map. The GLP-1 receptor is present on pancreatic beta cells, on gastric smooth muscle and enteric neurons, on vagal afferent terminals, in the area postrema and nucleus tractus solitarius of the brainstem, in the arcuate nucleus of the hypothalamus, in cardiac atria, and in the renal vasculature. Almost every clinical effect and almost every adverse effect maps onto one of those sites.

Biased agonism, stated carefully

When the GLP-1 receptor is activated it can couple to Gα_s, raising cyclic AMP, and it can recruit beta-arrestin, which contributes to receptor internalisation and desensitisation. An agonist that favours the first over the second is described as G-protein-biased. The therapeutic argument for bias is that sustained cAMP signalling without proportionate internalisation should produce a more durable effect at the same occupancy.

The evidence for that argument is real but narrower than its popularity suggests. Bias is measured in transfected cell systems at receptor densities that bear no relationship to a beta cell or a vagal afferent, and the translation from a bias factor in vitro to a clinical difference in vivo has been demonstrated convincingly for very few ligands.¹ The Journal’s position is that bias is a legitimate and probably important variable, that it is one of several plausible explanations for the differences observed between molecules, and that anybody presenting it as the explanation is ahead of the data.

Injection timing: what the kinetics permit

At steady state on a seven-day half-life the peak-to-trough variation across the dosing interval is modest — on the order of tens of per cent rather than folds. Moving the injection by twelve hours, or from one day of the week to another, does not meaningfully change total exposure. It does change when the highest concentrations occur relative to a person’s week.

Time to maximum concentration after subcutaneous injection is on the order of one to three days for the long-acting agonists, so an injection on Friday evening produces its concentration peak somewhere in the weekend. Whether that is desirable is a question about a person’s schedule, not about pharmacology. What the pharmacology does say is that consistency of interval matters more than consistency of hour, because the interval is what determines the accumulation ratio.

What GIP receptor agonism appears to contribute

Three explanations are current for the additional effect of GIP receptor agonism, and they are not mutually exclusive. The first is that GIP receptor activation in adipose tissue improves lipid handling and insulin sensitivity, permitting greater fat mobilisation at a given level of energy deficit. The second is central: GIP receptors are expressed in hypothalamic and hindbrain regions, and GIP receptor agonism may reduce nausea signalling, allowing higher GLP-1 receptor engagement to be tolerated. The third is that chronic GIP receptor agonism produces functional desensitisation that resembles antagonism, which would reconcile the apparently contradictory finding that both GIP agonists and GIP antagonists reduce body weight in preclinical work.

The second explanation is the most consequential if true, because it would mean the dual agonist’s advantage is partly a tolerability advantage rather than a distinct metabolic one — a difference that matters for how the drugs should be compared.²

The expression map, tissue by tissue

Pancreatic beta cells: receptor activation potentiates glucose-dependent insulin secretion, which is why the class does not cause hypoglycaemia in the way sulfonylureas do — the effect requires elevated glucose. Alpha cells: suppression of glucagon secretion, also glucose-dependent. Gastric smooth muscle and enteric neurons: reduced antral motility and delayed emptying. Vagal afferents: signalling to the brainstem that contributes to satiety and to nausea.

Brainstem — area postrema and nucleus tractus solitarius: integration of peripheral satiety signals, and the site most plausibly responsible for nausea and vomiting. Hypothalamic arcuate nucleus: modulation of POMC and AgRP neuron activity, the classical appetite circuit. Cardiac atria: heart-rate increase of a few beats per minute, consistently observed and of uncertain clinical significance. Renal vasculature and tubule: effects on natriuresis and glomerular haemodynamics that are the most plausible mechanism for the renal outcome findings.³

Delayed gastric emptying is the mechanism, not the complication

Slowed gastric emptying is frequently described as a side effect. It is more accurately described as a mechanism that becomes an adverse effect at sufficient magnitude. Delayed emptying blunts the post-prandial glucose excursion, which is part of the glycaemic benefit, and it produces early satiety, which is part of the weight effect. Beyond a threshold it produces nausea, vomiting, reflux and the sensation of food sitting undigested.

Two properties of the effect matter clinically. It is dose-dependent, and it exhibits partial tachyphylaxis: the magnitude of delay attenuates over weeks of continued exposure at a fixed dose, which is the physiological basis for the observation that tolerability improves if a dose is held rather than escalated. The residual delay at steady state is real and is the reason pre-procedural fasting guidance for this class exists at all.⁴

The heart-rate signal

A resting heart-rate increase of roughly two to four beats per minute is one of the most reproducible findings in the class, observed across molecules, doses and populations. The mechanism is probably direct: GLP-1 receptors are expressed in the sinoatrial node region, and receptor activation has chronotropic effects in isolated preparations.

What it means clinically is unresolved. The cardiovascular outcome trials that reported the heart-rate increase also reported reductions in major adverse cardiovascular events, so whatever the chronotropic effect represents it is not overwhelming the benefit in the populations studied. That is a statement about trial populations and event rates, not a mechanistic reassurance, and the Journal reports it as such.

Why any of this belongs in a general publication

An argument could be made that receptor pharmacology is a specialist concern and that readers need practical guidance instead. The Journal’s position is the opposite, for a specific reason: almost every piece of bad advice circulating about this drug class is a mechanistic error with a practical conclusion attached.

Escalating on a fixed calendar regardless of symptoms is an error about accumulation kinetics. Splitting a weekly dose into daily fractions to reduce side effects is an error about half-life and steady state. Assuming a molecule with GIP activity is simply a stronger version of one without is an error about selectivity. Expecting weight to keep falling indefinitely is an error about energy balance. In each case the practical advice is wrong because the mechanism was misunderstood, and in each case understanding the mechanism is not much harder than memorising the rule.

A note on sources

Everything above is drawn from the peer-reviewed pharmacology and clinical literature and from regulatory assessment reports, which are more informative than the papers on questions of dose selection and exposure. Where a claim rests on in-vitro work in transfected cells, this piece says so, because the translation of such work to human physiology has failed often enough in this field to deserve a standing caveat.

Where the Journal reports a trial number it states the estimand behind it, because the treatment-policy and trial-product estimands differ by two to three percentage points in the obesity programmes and the difference is routinely lost in secondary coverage. Nothing here is a recommendation, and none of the compounds discussed as research chemicals are approved for human use.

What has actually changed in the last three years

Three things, on the Journal’s assessment. First, the demonstration that a dual agonist could produce weight reduction approaching bariatric-surgical magnitude moved the field’s expectations, and with them the design of every subsequent programme. Second, the cardiovascular and renal outcome results reframed the class from metabolic-cosmetic to cardiometabolic, which changed reimbursement arguments far more than it changed prescribing.

Third, and least remarked, the pharmacology of oral administration became tractable. That is a manufacturing and access story as much as a scientific one: an oral small molecule has a completely different cost structure, cold-chain requirement and supply profile from an injectable peptide, and if it holds up in phase 3 it will do more to change who can get treated than any of the receptor science described above.

Two things follow practically from the pharmacology above, and only two. Consistency of dosing interval matters more than consistency of hour. And an interruption long enough to clear the drug is an interruption long enough to reset tolerability, which means resumption is a fresh escalation and not a continuation. Everything else in this piece is background.